NewLink Genetics Corp. (NASDAQ:NLNK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage presently has a $13.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 16.38% from the stock’s previous close. According […]
